Table 2 Inputs: Treatment effectiveness profiles
From: Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina
Parameter | SAXA + MET | SU + MET | Reference | Insulin | Reference |
|---|---|---|---|---|---|
HbA 1c | Â | Â | Â | Â | Â |
Reduction in year 1 (%) | −0.57 (0.041) | −0.66 (0.041) | [23] | −1.0 | Assumed |
Delay in creep (years) | 3.00 | 0.00 | 0.00 | ||
Body weight (kg) | −1,100 (0.017) | 1,100 (0.018) | [23] | 2,500 | [24] |
Adverse Effect | Â | Â | Â | Â | Â |
Hypoglycemic events | Â | Â | Â | Â | Â |
Number of symptomatic events | 0.04 (0.02) | 1.73 (0.08) | [23] | 10.00 | Assumed |
Probability of seriousness | 0.00 | 0.02 | [23] | 0.02 | [24] |
Discontinuation probability | 0.00 | 0.00 | Assumed | 0.00 | Assumed |